The pharmaceutical company Roche on Wednesday announced a program to help ensure developing countries have access to its antiviral Tamiflu, for “the management of a novel influenza strain defined by the WHO as having significant and current pandemic potential,” Reuters reports (Egenter, 7/1).
Read More…
Related Posts
- Pandemic Flu, Like Seasonal H1N1, Shows Signs Of Resisting Tamiflu
- Toward A Less Expensive Version Of The Anti-flu Drug Tamiflu
- Update On Person To Person Spread Of Swine Flu Resistant To Tamiflu, Wales
- In Their Own Words: Kids Offer Advice On H1N1 Flu
- Could Vaccination For Children Against Seasonal Flu Stop Immunity Developing Against Pandemic Strains?
- CT Scans Show Patients With Severe Cases Of H1N1 Are At Risk For Developing Acute Pulmonary Emboli
- Publix Pharmacies To Compound Tamiflu Into Oral Suspension
- Tamiflu Metabolite Measured In Japanese Sewage Discharge, River Water
- Walgreens To Compound Tamiflu Oral Suspension For Children In Response To Supply Shortage
- Walgreens To Offer Seasonal Flu Shots At More Than 7,000 Points Of Care Nationwide Beginning September 1st
- MDA, Walgreens Join Forces To Offer Seasonal Flu Shots
- Stanford Research Assesses Use Of Tamiflu, Relenza To Prevent Flu
- WHO Urges H1N1 Vaccine Producers To Give 10 Per Cent To Poor Countries
- Swine Infects 36 Countries So Far, 8,451 Cases, And 71 Confirmed Deaths
- Contextual adaptation of the Personnel Evaluation Standards for assessing faculty evaluation systems in developing countries: the case of Iran
Tags: countries, developing, discounted, efficacy, offer, roche, tamiflu
This entry was posted
on Friday, July 3rd, 2009 at 8:07 pm and is filed under Uncategorized.
You can follow any responses to this entry through the RSS 2.0 feed.
Both comments and pings are currently closed.
